Novo Nordisk Research Centre Oxford is an innovative target discovery
unit with a focus on identifying novel, game-changing therapies for
patients with type 2 diabetes and cardiometabolic diseases.
We employ advanced computational biology, state-of-the-art discovery
screening technologies, genetics and human-centric cell systems to
dissect pathophysiology and identify novel drug targets. The site is a
fusion of the best of academia, biotech and big pharma in order to
realize cutting-edge biology and start a target’s journey from bench
NNRCO operates at the boundaries of frontier science with a mandate
to find dynamic, agile and distinctive new ways of working to
diversify the company’s pipeline with disruptive medicines.